Back to News
Market Impact: 0.3

Guru Fundamental Report for JNJ

JNJNDAQ
Company FundamentalsAnalyst InsightsCorporate EarningsHealthcare & Biotech
Guru Fundamental Report for JNJ

Validea's guru fundamental report rates Johnson & Johnson (JNJ) at 77% using the Partha Mohanram P/B Growth Investor model, which targets low book-to-market stocks with sustained growth potential. As a large-cap growth stock in the Biotechnology & Drugs industry, JNJ largely aligns with the model's criteria, passing tests for profitability, cash flow, and sales variance. However, it notably fails criteria related to advertising and research and development as a percentage of assets, positioning its score just below the 80% threshold typically indicating 'some interest' from the strategy.

Analysis

Johnson & Johnson (JNJ) receives a moderately positive quantitative assessment from Validea's P/B Growth Investor model, scoring 77% based on Partha Mohanram's strategy. This score positions JNJ just below the 80% threshold that typically indicates initial interest from the model. The analysis highlights a dichotomy in the company's fundamentals: JNJ exhibits strong current operational health and stability, passing criteria for its book-to-market ratio, return on assets (ROA), cash flow from operations, and low variance in both ROA and sales. These factors suggest high-quality, consistent earnings. However, the model, which is designed to identify sustained future growth, flags JNJ for failing on two key forward-looking metrics: Advertising to Assets and Research and Development to Assets. For a large-cap firm in the Biotechnology & Drugs industry, these failures may indicate that, relative to its substantial asset base, current investment levels in marketing and innovation are not optimized for future outperformance according to this specific academic framework.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo

Market Sentiment

Overall Sentiment

moderately positive

Sentiment Score

0.50

Ticker Sentiment

JNJ0.60
NDAQ0.00

Key Decisions for Investors

  • Investors should view this 77% score as a signal of solid current fundamentals but should further scrutinize Johnson & Johnson's capital allocation, particularly R&D and marketing spend, to assess if they are sufficient to drive long-term growth.
  • For growth-oriented investors, the failure on R&D and Advertising to Assets warrants a deeper, peer-relative analysis to determine if this constitutes a genuine risk to future market leadership or simply a feature of JNJ's mature business model.
  • Investors with a quality or value focus may find the strong marks on profitability and stability (ROA, cash flow, low sales variance) attractive, but should weigh these against the model's suggestion of potential growth deceleration.